Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences
J Clin Oncol
.
2013 May 10;31(14):1709-12.
doi: 10.1200/JCO.2013.48.8825.
Epub 2013 Apr 8.
Authors
Emmanuel S Antonarakis
,
Mario A Eisenberger
PMID:
23569320
PMCID:
PMC4812821
DOI:
10.1200/JCO.2013.48.8825
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Male
Prostatic Neoplasms / drug therapy*
Grants and funding
P30 CA006973/CA/NCI NIH HHS/United States